Literature DB >> 24406265

Can we fix it? Evaluating the potential of placental stem cells for the treatment of pregnancy disorders.

J L James1, S Srinivasan2, M Alexander2, L W Chamley2.   

Abstract

In pregnancy disorders such as pre-eclampsia, intrauterine growth restriction (IUGR) and recurrent miscarriage a poorly functioning placenta is thought to be a major component of the disease process. However, despite their prevalence, we currently have no way to fix dysfunctional placentae or directly treat these disorders. Over the past two decades our understanding of the role that stem cells play in organ development and regeneration has expanded rapidly, and over the past 5 years the therapeutic use of stem cells to both regenerate damaged tissues, and act as potent modulators of diseased microenvironments, has become a reality in many organs including the heart, kidney, liver, skin and eye. Over its short lifespan the placenta undergoes rapid and continuous growth and differentiation, meaning that placental 'organogenesis' only truly ends at delivery, and thus stem cells are likely to play important roles in placental function for the duration of pregnancy. Two populations of stem cells exist in the placenta that contribute to this on-going growth and differentiation: trophoblast stem cells and mesenchymal stem cells. This review will address our current understanding of how each of these stem cell populations contributes to successful placental function, how epithelial and mesenchymal stem cell populations are being translated to the clinic in other fields, and whether these advances can teach us anything about how placental stem cells could be used to fix faulty placentae in the future.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IUGR; Placenta; Pre-eclampsia; Regenerative medicine; Stem cell

Mesh:

Year:  2013        PMID: 24406265     DOI: 10.1016/j.placenta.2013.12.010

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  10 in total

1.  Notch1 controls development of the extravillous trophoblast lineage in the human placenta.

Authors:  Sandra Haider; Gudrun Meinhardt; Leila Saleh; Christian Fiala; Jürgen Pollheimer; Martin Knöfler
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

2.  The role of DNA methylation in human trophoblast differentiation.

Authors:  Teena K J B Gamage; William Schierding; Daniel Hurley; Peter Tsai; Jackie L Ludgate; Chandrakanth Bhoothpur; Lawrence W Chamley; Robert J Weeks; Erin C Macaulay; Joanna L James
Journal:  Epigenetics       Date:  2018-12-05       Impact factor: 4.528

3.  Impaired Angiogenic Potential of Human Placental Mesenchymal Stromal Cells in Intrauterine Growth Restriction.

Authors:  Chiara Mandò; Paola Razini; Chiara Novielli; Gaia Maria Anelli; Marzia Belicchi; Silvia Erratico; Stefania Banfi; Mirella Meregalli; Alessandro Tavelli; Marco Baccarin; Alessandro Rolfo; Silvia Motta; Yvan Torrente; Irene Cetin
Journal:  Stem Cells Transl Med       Date:  2016-03-08       Impact factor: 6.940

Review 4.  An update on stem cell therapy for Asherman syndrome.

Authors:  Ariel Benor; Steven Gay; Alan DeCherney
Journal:  J Assist Reprod Genet       Date:  2020-05-22       Impact factor: 3.412

Review 5.  Significance of Placental Mesenchymal Stem Cell in Placenta Development and Implications for Preeclampsia.

Authors:  Yang Zhang; Yanqi Zhong; Li Zou; Xiaoxia Liu
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

6.  AMPK knockdown in placental trophoblast cells results in altered morphology and function.

Authors:  Erica A K Carey; Renee E Albers; Savannah R Doliboa; Martha Hughes; Christopher N Wyatt; David R C Natale; Thomas L Brown
Journal:  Stem Cells Dev       Date:  2014-08-18       Impact factor: 3.272

7.  Propagation of pure fetal and maternal mesenchymal stromal cells from terminal chorionic villi of human term placenta.

Authors:  Smitha Mathews; K Lakshmi Rao; K Suma Prasad; M K Kanakavalli; A Govardhana Reddy; T Avinash Raj; Kumarasamy Thangaraj; Gopal Pande
Journal:  Sci Rep       Date:  2015-05-15       Impact factor: 4.379

8.  PFKFB3-mediated glycometabolism reprogramming modulates endothelial differentiation and angiogenic capacity of placenta-derived mesenchymal stem cells.

Authors:  Yang Zhang; Yanqi Zhong; Weifang Liu; Fanghui Zheng; Yin Zhao; Li Zou; Xiaoxia Liu
Journal:  Stem Cell Res Ther       Date:  2022-08-02       Impact factor: 8.079

9.  Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia.

Authors:  Sonja Suvakov; Hajrunisa Cubro; Wendy M White; Yvonne S Butler Tobah; Tracey L Weissgerber; Kyra L Jordan; Xiang Y Zhu; John R Woollard; Fouad T Chebib; Natasa M Milic; Joseph P Grande; Ming Xu; Tamara Tchkonia; James L Kirkland; Lilach O Lerman; Vesna D Garovic
Journal:  Biol Sex Differ       Date:  2019-09-14       Impact factor: 5.027

10.  MicroRNA-30a contributes to pre-eclampsia through regulating the proliferation, apoptosis, and angiogenesis modulation potential of mesenchymal stem cells by targeting AVEN.

Authors:  Fangle Gu; Dan Lu; Liying Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.